Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07597005

Red Propolis Supplementation as a Strategy in Chronic Kidney Disease

The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.

Recruiting

Interested in participating?

Request Info

Key information

About this study

Chronic kidney disease (CKD) is associated with chronic systemic inflammation and oxidative stress, which contribute to disease progression and adverse outcomes. Red propolis is a natural substance rich in bioactive compounds with potential anti-inflammatory and antioxidant effects. Clinical evidence on its use in CKD patients is limited, and no studies have evaluated its impact on gene expression related to inflammation and oxidative stress. This randomized, double-blind, placebo-controlled trial will assess the effects of alcoholic extract of red propolis (200 mg/day for 8 weeks) on inflammatory and oxidative stress markers in patients with CKD stages 3-5 under conservative management. Blood samples will be collected at baseline and after intervention to evaluate routine biochemical parameters, inflammatory and oxidative stress markers, and gene expression. Nutritional status and dietary intake will also be assessed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with CKD stages 3-5 under conservative management

Exclusion criteria

  • pregnant,
  • lactating,
  • smoker
  • patients using antibiotics and antioxidant supplements in the last three months
  • patients with autoimmune and infectious diseases,
  • patients with cancer, liver disease, and AIDS

Treatment and study plan

Red Propolis

Dietary Supplement

Participants will receive 200mg of red propolis capsules per day for two months.

Placebo control

Other

Participants will receive 200mg of placebo capsules per day for two months.

Primary outcomes

  1. Change in inflammatory biomarkers

    Time frame: 8 weeks

    Changes in the IL-6 and TNF-α

Study contacts

Contact information is provided by the study sponsor or research team.

Denise Mafra, phd

CONTACT

[email protected]

21985683003

Sponsors and collaborators

Lead sponsor

Universidade Federal Fluminense

Other

Registry information

Official study title

Red Propolis as a Strategy to Modulate Inflammation and Oxidative Stress in Patients With Chronic Kidney Disease

Important dates

Study start
2025
Primary completion
2025
Study completion
2027
First posted
May 19, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.